Expand all sections

Semaglutide

Extended indication

Op dit moment heeft oraal semaglutide reeds een indicatie voor diabetes. De aan te vragen indicatie

Therapeutic value

No estimate possible yet
Registration phase

Clinical trials

Product

Active substance

Semaglutide
Domain

Metabolism and Endocrinology
Reason of inclusion

Indication extension
Main indication

Other metabolism and Endocrinology
Extended indication

Op dit moment heeft oraal semaglutide reeds een indicatie voor diabetes. De aan te vragen indicatie uitbreiding zal slaan op het behandelen van obesitas.
Manufacturer

Novo Nordisk
Portfolio holder

Novo Nordisk
Route of administration

Oral
Therapeutical formulation

Tablet
Budgetting framework

Extramural (GVS)

Registration

Registration route

Centralised (EMA)
ATMP

No
Submission date

2024
Expected Registration

2025
Orphan drug

No
Registration phase

Clinical trials

Therapeutic value

Therapeutic value

No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

References 
medicijnkosten.nl;
Additional remarks 
Gemiddelde kosten voor een tablet Rybelsus van 14 mg is €4,14 inclusief btw.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.